Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Cost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Arcadia Biosciences (RKDA) EBITDA (2016 - 2025)

Historic EBITDA for Arcadia Biosciences (RKDA) over the last 12 years, with Q3 2025 value amounting to -$1.2 million.

  • Arcadia Biosciences' EBITDA rose 3454.55% to -$1.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$3.4 million, marking a year-over-year decrease of 3283.87%. This contributed to the annual value of -$3.6 million for FY2024, which is 4021.63% up from last year.
  • Arcadia Biosciences' EBITDA amounted to -$1.2 million in Q3 2025, which was up 3454.55% from -$501000.0 recorded in Q2 2025.
  • Arcadia Biosciences' EBITDA's 5-year high stood at $2.1 million during Q1 2021, with a 5-year trough of -$9.3 million in Q4 2021.
  • For the 5-year period, Arcadia Biosciences' EBITDA averaged around -$2.1 million, with its median value being -$1.8 million (2024).
  • As far as peak fluctuations go, Arcadia Biosciences' EBITDA crashed by 32463.56% in 2022, and later surged by 13459.72% in 2024.
  • Arcadia Biosciences' EBITDA (Quarter) stood at -$9.3 million in 2021, then soared by 54.16% to -$4.2 million in 2022, then surged by 71.89% to -$1.2 million in 2023, then tumbled by 91.03% to -$2.3 million in 2024, then skyrocketed by 49.45% to -$1.2 million in 2025.
  • Its last three reported values are -$1.2 million in Q3 2025, -$501000.0 for Q2 2025, and $530000.0 during Q1 2025.